# Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

> **NCT00057343** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 400 (—)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Zevalin (ibritumomab tiuxetan)
- **DRUG:** Rituxan (rituximab)

## Key facts

- **NCT ID:** NCT00057343
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 400 (—)
- **Last updated:** 2006-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00057343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00057343, "Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00057343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*